TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
LAB

Standard Biotools Inc

Healthcare · Medical Devices · —

0.7498$ +1.1% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement LAB
Line item 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
43.3% 48.3% 54.5% 45.2% 34.5% 30.8% 29.3% 28.2% 36.8% 40.6% 44.1% 49.0% 45.4% 45.2% 39.7% 40.8% 62.2% 52.6% 51.7% 50.1%
56.7% 51.7% 45.5% 54.8% 65.5% 69.2% 70.7% 71.8% 63.2% 59.4% 55.9% 51.0% 54.6% 54.8% 60.3% 59.2% 37.8% 47.4% 48.3% 49.9%
243.7% 197.8% 91.3% 48.5% 38.8% 32.5% 31.7% 27.7% 37.3% 34.2% 36.8% 30.2% 26.6% 27.0% 26.4% 29.1% 38.2% 24.4% 35.8% 30.5%
89.2% 78.0% 70.6% 72.1% 70.9% 75.7% 117.2% 93.0% 89.8% 128.7%
395.2% 375.1% 238.0% 125.8% 108.9% 105.5% 105.2% 95.2% 98.5% 106.5% 126.0% 108.2% 97.2% 99.0% 97.3% 110.8% 156.5% 119.5% 148.8% 159.2%
-338.6% -323.4% -192.5% -71.0% -43.4% -43.3% -34.5% -25.2% -44.5% -43.7% -70.1% -57.3% -42.6% -44.2% -36.9% -51.7% -118.6% -72.0% -100.5% -109.3%
35.3% 38.4% 13.2% 11.3% 6.4% 7.2% 1.2% 0.0% 4.6% 5.1% 5.6% 5.7% 12.3% 3.6% 2.6% 2.9% 4.4% 4.3% 1.9% 0.0%
-368.1% -348.4% -193.2% -75.5% -50.1% -52.0% -36.1% -22.0% -49.6% -47.8% -76.8% -62.6% -54.4% -56.9% -39.2% -48.8% -197.0% -69.8% -79.3% -113.3%
3.0% 1.4% -1.0% -0.2% 0.2% 0.4% 0.3% 0.2% -4.2% -1.3% -4.0% -3.2% -2.1% -1.6% -0.8% -3.4% -2.9% 0.4% 0.3% -44.4%
-368.1% -349.8% -192.2% -75.3% -50.4% -52.4% -36.4% -22.2% -45.4% -46.5% -72.8% -59.4% -52.2% -55.3% -38.4% -45.4% -194.1% -70.2% -79.6% -87.8%
-310.0% -287.5% -170.2% -57.7% -40.3% -42.3% -32.1% -19.4% -33.1% -28.7% -54.0% -38.9% -27.5% -39.8% -25.0% -33.9% -177.2% -51.2% -67.7% -105.1%

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?